Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains. In this episode of the Vanguards of Health Care podcast, Connelly joins Bloomberg Intelligence biotech analyst Marc Engelsgjerd for a discussion of Elicio’s novel, lymph node-targeting vaccine platform, the company’s recent transition to the public markets via a reverse merger and the biotech scene in Boston’s booming Seaport district, where Elicio is based.  

Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains. In this episode of the Vanguards of Health Care podcast, Connelly joins Bloomberg Intelligence biotech analyst Marc Engelsgjerd for a discussion of Elicio’s novel, lymph node-targeting vaccine platform, the company’s recent transition to the public markets via a reverse merger and the biotech scene in Boston’s booming Seaport district, where Elicio is based.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare by Bloomberg Intelligence

Elicio’s Broad Cancer-Vaccine Ambitions

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/7a58ee84-0073-43a6-8396-b05f013ec075/transcript

“In five years in healthcare, every single person in America will have the same kind of quality of healthcare that Jeff Bezos has.” Akido Labs co-founder and CEO Prashant Samant joins Bloomberg Intelligence analyst Jonathan Palmer to explain why AI could turn concierge medicine from a luxury into a mass-market model. Samant traces Akido’s evolution from a health-data platform into a full-stack care-delivery system serving roughly 1 million patients, and details how Scope AI is designed to expand clinician capacity without removing physicians from the loop. The conversation explores Akido’s street-medicine work, value-based care, plans to enter 50 markets and why Samant believes the era of waiting months for a specialist could soon look obsolete.

&ldquo;In five years in healthcare, every single person in America will have the same kind of quality of healthcare that Jeff Bezos has.&rdquo; Akido Labs co-founder and CEO Prashant Samant joins Bloomberg Intelligence analyst Jonathan Palmer to explain why AI could turn concierge medicine from a luxury into a mass-market model. Samant traces Akido&rsquo;s evolution from a health-data platform into a full-stack care-delivery system serving roughly 1 million patients, and details how Scope AI is designed to expand clinician capacity without removing physicians from the loop. The conversation explores Akido&rsquo;s street-medicine work, value-based care, plans to enter 50 markets and why Samant believes the era of waiting months for a specialist could soon look obsolete.

Akido Bets AI Can Break Healthcare’s Scarcity Problem

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/2e0da06b-5d8d-47bd-9ae6-b4f90120b9b3/transcript

“We wanted to be kind of the catalyst of collision between these two worlds, bringing wearable devices with all of their simplicity and the delightfulness of the experience with medical devices, with their accuracy and their ability to actually drive better health outcomes,” Happy Health co-founder and CEO Dustin Freckleton says of the Happy Ring. In this Vanguards of Healthcare episode, Freckleton sits down with BI analyst Matt Henriksson for an in-depth interview about the Happy Ring and how the company miniaturized multiple sensor technologies into a ring that combines a consumer-friendly form factor with healthcare decision-making capabilities. The discussion also covers the company’s expansion path following its recent FDA approvals and Series A financing, as well as lessons learned from past experiences as it seeks to keep the process simple while developing the Happy Ring.

&ldquo;We wanted to be kind of the catalyst of collision between these two worlds, bringing wearable devices with all of their simplicity and the delightfulness of the experience with medical devices, with their accuracy and their ability to actually drive better health outcomes,&rdquo; Happy Health co-founder and CEO Dustin Freckleton says of the Happy Ring. In this Vanguards of Healthcare episode, Freckleton sits down with BI analyst Matt Henriksson for an in-depth interview about the Happy Ring and how the company miniaturized multiple sensor technologies into a ring that combines a consumer-friendly form factor with healthcare decision-making capabilities. The discussion also covers the company&rsquo;s expansion path following its recent FDA approvals and Series A financing, as well as lessons learned from past experiences as it seeks to keep the process simple while developing the Happy Ring.

Happy Health Develops a Wearable that Can Drive Healthcare Decision Making

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/14f83984-1730-4e73-b017-b4f200c9d5d8/transcript

“We don’t have any purpose-built technologies for the treatment of VT (ventricular tachycardia), and when I had a chance to look at what Field was building and the opportunity here to build out a new space and a new sector, it was very exciting to me,” Field Medical CEO Mark Turco explains regarding new areas for pulsed field ablation (PFA) innovation. In this episode of the Vanguards of Healthcare podcast, Turco and Field Medical Founder Steven Mickelsen sit down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about the potential benefits of the company’s next-generation PFA technology and how it’s designed to address the more demanding areas of cardiac arrhythmias, starting with VT. They dive further into the commercial strategy for its VERITAS VT and FIELD-PULSE pivotal studies, after promising first-in-human trial results.

&ldquo;We don&rsquo;t have any purpose-built technologies for the treatment of VT (ventricular tachycardia), and when I had a chance to look at what Field was building and the opportunity here to build out a new space and a new sector, it was very exciting to me,&rdquo; Field Medical CEO Mark Turco explains regarding new areas for pulsed field ablation (PFA) innovation. In this episode of the Vanguards of Healthcare podcast, Turco and Field Medical Founder Steven Mickelsen sit down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about the potential benefits of the company&rsquo;s next-generation PFA technology and how it&rsquo;s designed to address the more demanding areas of cardiac arrhythmias, starting with VT. They dive further into the commercial strategy for its VERITAS VT and FIELD-PULSE pivotal studies, after promising first-in-human trial results.

Field Medical Develops New PFA Tech to Treat More Patients

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/eb356412-8008-4c2d-9153-b4eb011697f9/transcript

Elicio’s Broad Cancer-Vaccine Ambitions

In 1 playlist(s)

Vanguards of Healthcare by Bloomberg Intelligence

Social links

Follow podcast

Recent clips